1. Bulevirtide monotherapy is safe and well tolerated in patients with chronic hepatitis D (CHD): An integrated safety analysis of 48-week data. (March 2023) Authors: Asselah, T.; Lampertico, P.; Aleman, S.; Bourliere, M.; Streinu-Cercel, A.; Bogomolov, P.; Morozov, V.; Stepanova, T.; Lazar, S.; Suri, V.; Manuilov, D.; Mercier, R.C.; Tseng, S.; Ye, L.; Flaherty, J.F.; Osinusi, A.; Brunetto, M.; Wedemeyer, H. Journal: Digestive and liver disease Issue: Volume 55(2023)Supplement 1 Page Start: S74 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Daclatasvir/peginterferon lambda‐1a/ribavirin in patients with chronic HCV infection and haemophilia who are treatment naïve or prior relapsers to peginterferon alfa‐2a/ribavirin. (24th June 2016) Authors: Santagostino, E.; Pol, S.; Olveira, A.; Reesink, H. W.; van Erpecum, K.; Bogomolov, P.; Xu, D.; Critelli, L.; Srinivasan, S.; Cooney, E. Journal: Haemophilia Issue: Volume 22:Number 5(2016:Sep.) Page Start: 692 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy of bulevirtide as monotherapy for chronic hepatitis D (CHD): Week 48 results from an integrated analysis. (March 2023) Authors: Lampertico, P.; Aleman, S.; Blank, A.; Bogomolov, P.; Chulanov, V.; Mamonova, N.; Morozov, V.; Sagalova, O.; Stepanova, T.; Suri, V.; Manuilov, D.; Ye, L.; Flaherty, J.F.; Osinusi, A.; Cornberg, M.; Brunetto, M.; Wedemeyer, H. Journal: Digestive and liver disease Issue: Volume 55(2023)Supplement 1 Page Start: S73 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗